Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont is a selective antagonist of corticotropin-releasing factor (CRF) type 1 receptor that works to reduce excessive ACTH secretion from the pituitary. … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently

    Categories: Corticotropin-releasing Factor Type 1 Receptor Antagonist
  2. Drug

    Raxtozinameran

    go.drugbank.com/drugs/DB18228
    ApprovedInvestigational

    It works by binding to the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a transmembrane glycoprotein that plays a vital role in viral pathogenesis, evolutions … [A273680] Raxtozinameran was first approved by the FDA and EMA through emergency use in December 2020.[L52565,L39272]

    Synonyms: messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)Products: COMIRNATY® VACUNA DE ARNM CONTRA COVID-19
  3. Drug

    Ethotoin

    go.drugbank.com/drugs/DB00754
    Approved

    The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of seizure activity rather than to abolish the primary focus of seizure discharges. … The mechanism of action is probably very similar to that of phenytoin.

  4. Drug

    Pentostatin

    go.drugbank.com/drugs/DB00552
    ApprovedInvestigational

    The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia.

  5. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).

  6. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical modification in effort to improve the gastrointestinal tolerability of the drug. … It displays high permeability to penetrate into synovial joints where in patients with osteoarthritis and related conditions, the loss of articular cartilage in the area causes joint pain, tenderness,

  7. Drug

    Desogestrel

    go.drugbank.com/drugs/DB00304
    ApprovedInvestigational

    Desogestrel, a prodrug, is a third generation progestogen[A176315] and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. … [F4127] In the US, desogestrel is found only in combination with [ethinyl estradiol].

    Mixtures: DESOGESTREL E ETINILESTRADIOLO ARISTO, DESOGESTREL E ETINILESTRADIOLO ARISTOCategories: Sex Hormones and Modulators of the Genital System
  8. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.

  9. Drug

    Silver

    go.drugbank.com/drugs/DB12965
    ApprovedInvestigational

    Silver and its compounds have been used in trials studying the management of dental caries since the 1800s, and they may be found in dental pastes as an active ingredients. … Silver (Ag) is a chemical element that belongs in the family of transition metals in the periodic table. It has a high electrical conductivity, thermal conductivity, and reflectivity.

  10. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. … Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.

    Categories: Bispecific CD19-directed CD3-directed T Cell EngagerProducts: BLİNCYTO 38,5 MCG İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE TOZ VE ÇÖZELTİ, 1 ADET